Accessibility Menu

Idexx Laboratories(FRA) IX1

Market Cap€36.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€480.30
+3.02%
+14.10Today

Idexx Laboratories Financials at a Glance

Market Cap

€36.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€3.90K

Net Income (TTM)

€977.27

EPS (TTM)

€12.20

P/E Ratio

38.40

Dividend

€0.00

Beta (Volatility)

0.03 (Low)

Price

€480.30

Volume

34

Open

€472.80

Previous Close

€480.30

Daily Range

€472.80 - €480.30

52-Week Range

€450.10 - €665.80

Estimated Earnings Date

N/A

IX1 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Idexx Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Industry

Healthcare Equipment and Supplies

Employees

11,000

CEO

Michael Erickson, PhD

IX1 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

73.67%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

2.60%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€36.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.78M

Volume

34

Avg. Volume

12.106

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Idexx Laboratories Performance Analysis

Idexx Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,204,002,17917.8%
20232023-12-31EUR 3,386,273,3925.7%
20242024-12-31EUR 3,603,159,2006.4%
20252025-12-31EUR 3,813,384,7985.8%
Idexx Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 7.644.9%
20232023-12-31EUR 9.3121.9%
20242024-12-31EUR 9.865.9%
20252025-12-31EUR 11.5917.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€1.05K

+1.1%

Gross Profit

€670.43

+1.1%

Gross Margin

64.07%

+1.0%

Market Cap

€36.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€3.36

N/A

Employees

11,000

N/A

Net Income

€291.05

+1.1%

EBITDA

€401.69

+1.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€1.13K

-5.3%

Total Debt

€958.70

+0.9%

Accounts Receivable

€620.45

+1.2%

Inventory

€342.50

+1.0%

Long Term Debt

€350.19

+0.7%

Short Term Debt

€608.51

+1.1%

Return on Assets

33.42%

+1.1%

Return on Invested Capital

45.40%

+1.1%

Free Cash Flow

€278.63

+2.3%

Operating Cash Flow

€299.99

+2.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About IX1

What is the current price of Idexx Laboratories?

Idexx Laboratories is trading at €480.30 per share.

What is the 52-week range for Idexx Laboratories?

Over the past 52 weeks, Idexx Laboratories has traded between €450.10 and €665.80.

How much debt does Idexx Laboratories have?

As of the most recent reporting period, Idexx Laboratories reported total debt of €958.70M.

How much cash does Idexx Laboratories have on hand?

Idexx Laboratories reported €172.25M in cash and cash equivalents in its most recent financial results.

What is Idexx Laboratories’s dividend yield?

Idexx Laboratories does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.